Pexastimogene devacirepvec

Drug Profile

Pexastimogene devacirepvec

Alternative Names: JX-594; Pexa-Vec; TG-6006; thymidine kinase-deactivated Vaccinia virus and GM-CSF

Latest Information Update: 01 Apr 2016

Price : $50

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Green Cross; Jennerex; National Cancer Institute (France); SillaJen Biotherapeutics; Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Renal cell carcinoma; Solid tumours
  • Phase I/II Breast cancer; Malignant melanoma; Soft tissue sarcoma
  • Phase I Colorectal cancer
  • Preclinical Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 08 Mar 2016 Transgene plans to initiate a phase I/II trial for Solid tumours (Combination therapy, late-stage disease)
  • 28 Jan 2016 Phase-II clinical trials in Solid tumours (Neoadjuvant therapy, Late-stage disease, Metastatic disease) in United Kingdom (IV)
  • 01 Dec 2015 Jennerex Biotherapeutics completes a phase II trial in Hepatocellular carcinoma (Combination therapy; Inoperable/Unresectable) in South Korea (NCT01171651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top